



Release date: 08/02/2016

Mirada Medical of Oxford, UK is chosen to supply the prestigious Netherlands Cancer Institute (NKI) with ground breaking RTx Radiotherapy fusion and contouring software.

Oxford based Mirada Medical has been selected by the NKI, a world-class comprehensive cancer centre, to supply image fusion and contouring software. This patented software supports the planning for radiotherapy ultimately improving treatment for cancer patients. NKI specialises in pioneering novel radiotherapy techniques, many of which are adopted by radiotherapy departments across Europe and the world.

*“Advanced radiotherapy protocols can deliver significant improvements to patient outcomes, however many such techniques rely on accurate processing and analysis of large amounts of imaging data: a task for which conventional systems were not designed for and find challenging.” states **Dr. Timor Kadir, Mirada Chief Science and Technology Officer**. He continues, “The challenge in today’s clinic is how to deploy such novel therapy techniques in a robust, repeatable and efficient manner. This is what Mirada’s technology and products are designed to deliver.”*

Radiotherapy, alongside chemotherapy and surgery, is one of the mainstays of modern cancer treatment. However, treatment must be carefully optimised to ensure radiation given to healthy tissue is minimised. Mirada’s RTx software helps the treatment specialist to accurately define the tumorous tissue so healthy tissue can be avoided when giving treatment. This technology helps the doctors to deliver improved patient care.

Mirada’s technology will support the NKI in efficiently delivering state-of-the-art cancer care by increasing workflow efficiency through its unique automation technology, whilst at the same time facilitating the advancement in radiotherapy in the development of new protocols. *“Working with NKI is one of the best relationships we could have in order to incorporate emerging treatment protocols into the wider RT workflow, resulting in better cancer care. This really cements further the position of Mirada in Europe as the foremost image registration company.” **Matthieu Leclerc-Chalvet, Managing Director of Mirada**.*

*“Technology is a major part of our treatment and workflow improvement strategy. We chose Mirada medical because their contouring solution allows us the flexibility to push boundaries in research whilst using robust workflows we can trust in a clinical setting as well. With growing patient numbers and treatment complexity, increasing efficiency and flexibility whilst improving quality and precision has become imperative.” Explains **Dr. Peter Remeijer from NKI**.*

About Mirada Medical Ltd

Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, Multidisciplinary meetings and elsewhere.

Mirada’s technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada’s world headquarters in Oxford, England. For more information about Mirada Medical products visit <http://www.mirada-medical.com>

RTxTM and Mirada Medical are trademarks of Mirada Medical Ltd.

For more information, please contact:

World Headquarters:

Oxford Centre for Innovation

New Road, Oxford

OX1 1BY

United Kingdom Tel: +44(0)1865 261410